ACRS.NASDAQAclaris Therapeutics, INC

Form 4: Aclaris Therapeutics CEO Neal Walker Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Aclaris Therapeutics, INC
🔒Login to Follow

CEO Neal Walker reports acquisition and disposal of Aclaris Therapeutics stock related to restricted stock units.

Summary

  • On April 1, 2025, Neal Walker, CEO of Aclaris Therapeutics, reported transactions involving the company's common stock.
  • Walker acquired 9,467 shares through the vesting of restricted stock units.
  • Simultaneously, 3,042 shares were disposed of to cover tax withholding obligations at a price of $1.48 per share.
  • Following these transactions, Walker directly owns 1,473,332 shares of Aclaris Therapeutics.
  • The restricted stock units vest in equal monthly installments over 15 months beginning March 1, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors about the buying and selling activities of company executives and directors.

Stakeholder Impact

  • The transactions may provide insights to shareholders regarding management's perspective on the company's stock value.

Key Dates

DateDescription
March 1, 2024Start date for monthly vesting of restricted stock units over 15 months.
April 1, 2025Date of stock acquisition and disposal transactions.
April 3, 2025Date of signature for the Form 4 filing.

Keywords

Aclaris Therapeutics, Neal Walker, ACRS, Stock Transactions, Form 4, Restricted Stock Units, CEO, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.